TARGET for acute intervention in ischaemic stroke is the penumbra, a zone of incomplete cerebral ischaemia, where neurones are functionally inactive but still viable. The development of the penumbra is a timelimited condition where cells will die in the ensuing hours to days, owing to a cascade of biochemical events, the so-called 'ischaemic cascade' (see Box 1).
Compounds that interfere with these biochemical steps have been demonstrated to be neuroprotective in preclinical models of stroke. A fraction of these have entered clinical development and some of those that survived early safety trials have been studied in randomized double-blind placebo-controlled efficacy trials (Phase III trials). Such trials require the courageous participation of many stroke patients, a 24-hours-a-day commitment of physicians from many centres and usually significant financial investment from a pharmaceutical company. The resources required to complete such a trial are estimated to be about 30-40 million US dollars 1 . Despite these efforts, all Phase III trials have so far failed to demonstrate efficacy of neuroprotective agents (Table 1) .
Na

؉
-channel blockers
The anticonvulsant phenytoin blocks voltagedependent Na ϩ channels and reduces infarct size in both permanent and reperfusion models of focal brain ischaemia in rodents 24, 25 . Fosphenytoin is a prodrug of phenytoin that has been evaluated in a Phase III trial. Enrolment was halted after 462 patients had been included because no differences in primary or secondary endpoints were found in an interim analysis 2 .
Ca
2؉ -channel blockers
One obvious treatment strategy for stroke involves the regulation of Ca 2ϩ entry into the cell using inhib- . However, their potency is less th of glutamate-receptor antagonists. Nimodipine ha studied most extensively and, in contrast to its cial effects in subarachnoid haemorrhage, it h duced unimpressive results in acute cerebral isch The intravenous administration even worsened ou because of detrimental haemodynamic effects 8 . A analysis covering nine studies with oral nimo (120 mg/day) suggested a possible benefit wh drug was given within the first 12 h after onset of toms 27 . The VENUS (very early nimodipine use in trial, which was conducted to confirm this hyp in a prospective manner, has been stopped beca an interim analysis, no benefit of nimodipine b evident 
Glutamate inhibition or GABA stimulation
Inhibitors of glutamate receptors, particularly that block NMDA receptors, can reduce infarctio ume and neurological deficits in permanent a perfusion models of focal cerebral ischaemia 28 . T of several NMDA-receptor antagonists was discon in Phase I and Phase II studies because of unacce adverse effects. The major problems with thes pounds are psychomimetic effects (agitation, h nations, paranoia and delirium), sedation, cataton concerns about potential neurotoxicity 29 . Only s a competitive antagonist at the NMDA binding the NMDA receptor, and aptiganel, a non-comp drugs have been developed that have the potential to limit ischaemic brain damage and im outcome for patients.While promising results with these drugs have been achieved in animal s models, all Phase III trials conducted so far indicate that these drugs have failed to live up to promise. Despite the limits of animal models, which cannot mimic the clinical situatio disappointing results of neuroprotective trials might largely be due to methodological prob Future trials with neuroprotective drugs should be performed in stroke (care) units,after suff information regarding therapeutic time window, dosage, duration of therapy and safety has gathered from pilot studies, and a better selection of target patients has been made. Much o information can now be obtained by techniques that visualize the penumbra, such as com diffusion-weighted and perfusion MRI.Consideration should also be given to clinical trials with designed combinations of treatments.
